Search

Your search keyword '"Munoz, Flor M."' showing total 706 results

Search Constraints

Start Over You searched for: Author "Munoz, Flor M." Remove constraint Author: "Munoz, Flor M."
706 results on '"Munoz, Flor M."'

Search Results

2. CONTRIBUTORS

3. Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients

6. Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis

8. Cumulative Febrile, Respiratory, and Gastrointestinal Illness Among Infants in Rural Guatemala and Association With Neurodevelopmental and Growth Outcomes

9. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn

10. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

13. Incidence Rates of Medically Attended COVID-19 in Infants Less Than 6 Months of Age

15. Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review

16. Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients.

17. Postnatal Zika and Dengue Infection and Their Effects on Neurodevelopment Among Children Living in Rural Guatemala

18. 1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020

19. 385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2

22. 362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series

23. 462. Infant antibody titers at birth following maternal COVID-19 vaccination and protection against infection in the first 6 months of life

24. 1101. Antiviral Prescription in Children with Influenza in Emergency Departments (ED): New Vaccine Surveillance Network (NVSN), 2016–2020

25. 1742. Predictors of Antiviral Receipt for Influenza in Hospitalized U.S. Children, New Vaccine Surveillance Network (NVSN), 2016–2020

26. Maternal and perinatal health research during emerging and ongoing epidemic threats: a landscape analysis and expert consultation

27. Applicability of the GAIA Maternal and Neonatal Outcome Case Definitions for the Evaluation of Adverse Events Following Vaccination in Pregnancy in High-income Countries

31. Contributors

34. Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study.

35. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients

39. Contributors

40. Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data

42. Respiratory Syncytial Virus Vaccination During Pregnancy and Effects in Infants

43. Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines

46. Are the first 1,000 days of life a neglected vital period to prevent the impact on maternal and infant morbimortality of infectious diseases in Latin America? Proceedings of a workshop of experts from the Latin American Pediatric Infectious Diseases Society, SLIPE.

47. Standardizing case definitions for monitoring the safety of maternal vaccines globally: GAIA definitions, a review of progress to date

Catalog

Books, media, physical & digital resources